Markers of Inflammation in Sarcoidosis: Blood, Urine, BAL, Sputum, and Exhaled Gas

Clinics in Chest Medicine

Volumn 29, Issue 3, 2008, Pages 445-458

  Bargagli, E ^a   Mazzi, A ^a   Rottoli, Paola ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHITOTRIOSIDASE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE; LYSOZYME;

BLOOD; DISEASE MARKER; ENZYME ACTIVITY; EXPIRED AIR; HUMAN; INFLAMMATION; LUNG LAVAGE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SARCOIDOSIS; URINE;

BIOLOGICAL MARKERS; BREATH TESTS; BRONCHOALVEOLAR LAVAGE FLUID; HUMANS; SARCOIDOSIS, PULMONARY; SEVERITY OF ILLNESS INDEX; SPUTUM;

EID: 44649101444     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2008.03.004     Document Type: Review

References (134)

1. Baughman R.P., Lower E.E., and du Bois R.M. Sarcoidosis. Lancet 361 (2003) 1111-1118
2. Moller D.R. Potential etiologic agents in sarcoidosis. Proc Am Thorac Soc 4 (2007) 465-468
3. Drent M., and Costabel U. Sarcoidosis. European Respiratory Monograph 10 32 (2005) 13
4. Dai H., Guzman J., Chen B., et al. Production of soluble TNF receptor and TNF alpha by alveolar macrophages in sarcoidosis and extrinsic allergic alveolitis. Chest 127 (2005) 251-256
5. Ziegenhagen M.W., Rothe M.E., Zissel G., et al. Exaggerated TNF alpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 19 (2002) 185-190
6. Iannuzzi M.C., Rybicki B.A., and Teirstein A.S. Sarcoidosis. N Engl J Med 357 (2007) 2153-2165
7. Aladesanmi O.A. Sarcoidosis: an update for the primary care physicians. MedGenMed 6 (2004) 7
8. Sharma O.P., Smith I., Maguire G., et al. Clinical value of ACE genotyping in diagnosis of sarcoidosis. Lancet 349 (1997) 1602-1603
9. Stokes G.S., Monaghan J.C., Schrader A.P., et al. Influence of ACE genotype on interpretation of diagnostic tests for serum ACE activity. Aust N Z J Med 29 (1999) 315-318
10. Rothkrantz-Kos S., van Dieijen-Visser M.P., Mulder P.G.H., et al. Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis. Clin Chem 49 (2003) 1510-1517
11. Ziegenhagen M.W., Rothe M.E., Schlaak M., et al. BAL and serological parameters reflecting the severity of sarcoidosis. Eur Respir J 21 (2003) 407-413
12. Rottoli P., and Bargagli E. Is bronchoalveolar lavage obsolete in the diagnosis of interstitial lung disease?. Curr Opin Pulm Med 9 (2003) 418-425
13. Kantrow S.P., Meyer K.C., Kidd P., et al. The CD4/CD8 ratio in BAL fluid is highly variable. Eur Respir J 10 (1997) 2716-2721
14. Hunninghake G.W., and Crystal R.G. Pulmonary sarcoidosis: a disorder mediated by excess helper T lymphocyte activity at sites of disease activity. N Engl J Med 305 (1981) 429-434
15. Haslam P.L., and Baughman R.P. Guidelines for measurement of acellular components and standardization of BAL. Eur Respir J 9 (1999) 25-27
16. Baughman R.P., and Drent M. Role of BAL in interstitial lung diseases. Clin Chest Med 22 (2001) 331-341
17. Lieberman J. Elevation of serum angiotensin-converting enzyme (ACE) level in sarcoidosis. Am J Med 59 (1975) 365-372
18. Studdy P.R., Lapworth R., and Bird R. Angiotensin-converting enzyme and its clinical significant: a review. J Clin Pathol 36 (1983) 938-947
19. Gronhagen-Riska C., Kuppa K., Fyhrquist F., et al. Angiotensin-converting enzyme and lysozyme in silicosis and asbestosis. Scand J Respir Dis 59 (1978) 228-231
20. Brice E.A., Friedlander W., Bateman E.D., et al. Serum angiotensin-converting enzyme activity, concentration, and specific activity in granulomatous interstitial lung disease, tuberculosis, and COPD. Chest 107 3 (1995) 706-710
21. Lieberman J., Nosal A., Schleissner L.A., et al. Update on SACE assays for diagnosis and evaluation of sarcoidosis (1974), University Park Press, Baltimore (MD)
22. Lieberman J., and Rea T.H. Serum angiotensin-converting enzyme in leprosy and coccidioidomycosis. Ann Intern Med 87 (1977) 422-425
23. Casal J.A., Lacerda L., Perez L.F., et al. Relationships between serum markers of monocyte/macrophage activation in type 1 Gaucher's disease. Clin Chem Lab Med 40 (2002) 52-55
24. Kennon B., and Konnell J.M. ACE gene polymorphism and diabetic complications: is there a connection?. BioDrugs 14 (2000) 73-81
25. Smallridge R.C., Rogers J., and Verma P.S. Serum angiotensin-converting enzyme: alterations in hyperthyroidism, hypothyroidism and subacute thyroiditis. JAMA 250 (1983) 2489-2493
26. Matsuki K., and Sakata T. Angiotensin-converting enzyme in diseases of the liver. Am J Med 73 (1982) 549-551
27. Lieberman J., Schleissner L.A., Nosal A., et al. Clinical correlations of serum angiotensin-converting enzyme in sarcoidosis: a longitudinal study of serum ACE, 67 gallium scans, chest roentgenograms and pulmonary functions. Chest 84 (1983) 522-528
28. Schurmann M. Angiotensin converting enzyme gene polymorphism in patients with pulmonary sarcoidosis: impact on disease severity. Am J Pharmacogenomics 3 (2003) 233-243
29. Cambien F., Alhenc-Gelas F., Herbeth B., et al. Familial resemblance of plasma ACE level: the Nancy study. Am J Hum Genet 43 (1998) 774-780
30. Rigat B., Hubert C., Alhenc-Gelas F., et al. An insertion/deletion polymorphism in the angiotensin I converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86 (1990) 1343-1346
31. Kruit A., Grutters J.C., Gerritsen W.B.M., et al. ACE I/D-corrected Z-scores to identify normal and elevated ACE activity in sarcoidosis. Respir Med 101 (2007) 510-515
32. Alia P., Mana J., Capdevila O., et al. Association between ACE gene I/D polymorphism and clinical presentation and prognosis of sarcoidosis. Scand J Clin Lab Invest 65 (2005) 691-697
33. Costabel U., and Tescheler H. Biochemical changes in sarcoidosis. Clin Chest Med 18 (1997) 827-842
34. Baudin B. Angiotensin I-converting enzyme (ACE) for sarcoidosis diagnosis. Pathol Biol 53 (2005) 183-188 [in French]
35. Bargagli E., Margollicci M., Perrone M., et al. Chitotriosidase levels in BAL of patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 24 (2007) 59-64
36. Hankiewicz J., and Swierczek E. Lysozyme in human body fluids. Clin Chim Acta 57 3 (1974) 205-209
37. Prior C., Barbee R.A., Evans P.M., et al. Lavage versus serum measurements of lysozyme, angiotensin-converting enzyme and inflammatory markers in pulmonary sarcoidosis. Eur Respir J 3 (1990) 1146-1154
38. Selroos O.B. Biochemical marker in sarcoidosis. Crit Rev Clin Lab Sci 24 (1986) 185-216
39. Gronhagen-Riska C. Angiotensin-converting enzyme: activity and correlation with serum lysozime in sarcoidosis, other chest or lymph node disease and healthy persons. Scand J Respir Dis 60 (1979) 83-93
40. Khan K., Perillie P.E., and Finch S.C. Serum lysozyme in pulmonary tuberculosis. Am J Med Sci 265 (1973) 297-302
41. Turton C.W.G., Grundy E., Firth G., et al. Value of measuring serum angiotensin-converting enzyme and serum lysozyme in the management of sarcoidosis. Thorax 34 (1979) 57-62
42. Tomita H., Sato S., Matsuda R., et al. Serum lysozime levels and clinical features of sarcoidosis. Lung 177 (1999) 161-167
43. Boot R.G., Bussink A.P., Verhoek M., et al. Marked differences in tissue-specific expression of chitinases in mouse and man. J Histochem Cytochem 53 (2005) 1283-1292
44. Wajner A., Michelin K., Burin M.G., et al. Biochemical characterisation of chitotriosidase enzyme: comparison between normal individuals and patients with Gaucher and with Niemann-Pick diseases. Clin Biochem 37 (2004) 893-897
45. Michelakakis H., Dimitriou E., and Labadaridis I. The expanding spectrum of disorders with elevated plasma chitotriosidase activity: an update. J Inherit Metab Dis 27 (2004) 705-706
46. Artieda M., Cennaro A., Ganan A., et al. Serum chitotriosidase in subjects with atherosclerosis disease. Arterioscler Thromb Vasc Biol 23 (2003) 1645-1652
47. Vellodi A., Foo Y., and Cole T.J. Evaluation of three biochemical markers in the monitoring of Gaucher disease. J Inherit Metab Dis 28 (2005) 585-592
48. Brinkman J., Wijburg F.A., Hollak C.E., et al. Plasma chitotriosidase and CCL18: early biochemical surrogate markers in type B Niemann-Pick disease. J Inherit Metab Dis 28 (2005) 13-20
49. Grosso S., Margollicci M.A., Bargagli E., et al. Serum levels of chitotriosidase as a marker of disease activity and clinical stage in sarcoidosis. Scand J Clin Lab Invest 64 (2004) 57-62
50. Bargagli E, Bianchi N, Margollicci M, et al. Chitotriosidase and soluble IL-2 receptor: comparison of two markers of sarcoidosis severity. Scand J Clin Lab Invest, in press.
51. Bargagli E., Margollicci M., Nikiforakis N., et al. Chitotriosidase activity in serum of patients with sarcoidosis and pulmonary tuberculosis. Respiration 74 (2007) 548-552
52. Bargagli E., Margollicci M.A., Luddi A., et al. Chitotriosidase in BAL of patients with diffuse lung diseases. Respir Med 101 (2007) 2176-2181
53. Brunner J., Scholl-Burgi S., and Zimmerhackl L.B. Chitotriosidase as a marker of disease activity in sarcoidosis. Rheumatol Int 27 (2007) 1171-1172
54. Gurrieri G., Bortoli M., Brunetta E., et al. Cytokines, chemokines and other biomolecular markers in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 22 (2005) S9-S14
55. Antoniou K., Tsiligianni I., Kyriakou D., et al. Perforin down-regulation and adhesion molecules activation in pulmonary sarcoidosis. Chest 129 (2006) 1592-1598
56. Kurumagawa T., Seki S., Kobayashi H., et al. Characterization of bronchoalveolar lavage T cell subsets in sarcoidosis on the basis of CD57, CD4 and CD8. Clin Exp Immunol 133 3 (2003) 438-447
57. Semenzato G., Bortoli M., and Agostini C. Applied clinical immunology in sarcoidosis. Curr Opin Pulm Med 8 5 (2002) 441-444
58. Grutters J.C., Fellrath J.M., Mulder L., et al. Serum soluble IL2 receptor measurement in patients with sarcoidosis. Chest 124 (2003) 186-195
59. Prasse A., Katic C., and Germann M. Phenotyping sarcoidosis from a pulmonary perspective. Am J Respir Crit Care Med 177 3 (2008) 330-336
60. Eklund A., and Blaschke E. Elevated serum neopterin levels in sarcoidosis. Lung 164 6 (1986) 325-332
61. Lacronique J., Auzeby A., Valeyre D., et al. Urinary neopterin in pulmonary sarcoidosis: relationship to clinical and biologic assessment of the disease. Am Rev Respir Dis 139 6 (1989) 1474-1478
62. Muller-Quernheim J. Serum markers for the staging of disease activity of sarcoidosis and other interstitial lung diseases of unknown etiology. Sarcoidosis Vasc Diffuse Lung Dis 15 (1998) 22-37
63. Müller-Quernheim J. Sarcoidosis: immunopathogenetic concepts and their clinical application. Eur Respir J 12 (1998) 716-738
64. Fehrenbach H., Zissel G., Goldmann T., et al. Alveolar macrophages are the main source for tumour necrosis factor-α in patients with sarcoidosis. Eur Respir J 21 (2003) 421-428
65. Prasse A., Georges C.G., Biller H., et al. Th1 cytokine pattern in sarcoidosis is expressed by bronchoalveolar CD4+ and CD8+ T cells. Clin Exp Immunol 122 (2000) 241-248
66. Mollers M., Aries S.P., Dromann D., et al. Intracellular cytokine repertoire in different T cell subsets from patients with sarcoidosis. Thorax 56 (2001) 487-493
67. Wahlström J., Katchar K., Wigzell H., et al. Analysis of intracellular cytokines in CD4(+) and CD8(+) lung and blood T cells in sarcoidosis. Am J Respir Crit Care Med 163 (2001) 115-121
68. Marques L.J., Zheng L., Poulakis N., et al. Pentoxifylline inhibits TNF alpha production from human alveolar macrophages. Am J Respir Crit Care Med 159 (1999) 508-511
69. Zissel G., Ernst M., Rabe K., et al. Human alveolar epithelial cells type II are capable of regulating T-cell activity. J Investig Med 48 (2000) 66-75
70. Piguet P.F., Ribaux C., Karpuz V., et al. Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis. Am J Pathol 143 (1993) 651-655
71. Somoskovi A., Zissel G., Seitzer U., et al. Polymorphism at position -308 in the promoter region of the TNF-α and in the first intron of the TNF-β genes and spontaneous and lipopolysaccharide-induced TNF-α release in sarcoidosis. Cytokine 11 (1999) 882-887
72. Medica I., Kastrin A., Maver A., et al. Role of genetic polymorphisms in ACE and TNF-alpha gene in sarcoidosis: a meta-analysis. J Hum Genet 52 10 (2007) 836-847
73. Dai H., Guzman J., Chen B., et al. Increased expression of apoptosis signalling receptors by alveolar macrophages in sarcoidosis. Eur Respir J 13 (1999) 1451-1454
74. Kieszko R., Krawczyk P., Chocholska S., et al. Tumor necrosis factor receptors (TNFRs) on T lymphocytes and soluble TNFRs in different clinical courses of sarcoidosis. Respir Med 101 (2007) 645-654
75. Hino T., Nakamura H., Shibata Y., et al. Elevated levels of type II solubile tumor necrosis factor receptors in the bronchoalveolar lavage fluids of patients with sarcoidosis. Lung 175 (1997) 187-193
76. Yamaguchi E., Itoh A., Hizawa N., et al. The gene polymorphism of tumor necrosis factor-ß, but not that of tumor necrosis factor-α, is associated with the prognosis of sarcoidosis. Chest 119 (2001) 753-761
77. Border W.A., and Noble N.A. Transforming growth factor β in tissue fibrosis. N Engl J Med 10 (1994) 1286-1292
78. Moses H.L., Yang E.Y., and Pietenpol J.A. TGF β stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 63 (1990) 245-247
79. Zissel G., Schlaak J., Schlaak M., et al. Regulation of cytokine release by alveolar macrophages treated with interleukin-4, interleukin-10, or trasforming growth factor beta. Eur Cytokine Netw 7 (1996) 59-66
80. Yamamoto H., Hirayama M., Genyea C., et al. TGF β mediates natural suppressor activity of IL-2 activated lymphocytosec. J Immunol 149 (1994) 197-204
81. Limper A.H., Colby T.V., Sanders M.S., et al. Immunohistochemical localization of TGF β1 in the non necrotizing granulomas of pulmonary sarcoidosis. Am J Respir Crit Care Med 149 (1994) 197-204
82. Zissel G., Homolka J., Schlaak J., et al. Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis. Am J Respir Crit Care Med 154 (1996) 713-719
83. Kruit A., Grutters J.C., Ruven H.J., et al. Transforming growth factor-ß gene polymorphisms in sarcoidosis patients with and without fibrosis. Chest 129 (2006) 1584-1591
84. Bäumer I., Zissel G., Schlaak M., et al. Th1/Th2 cell distribution in pulmonary sarcoidosis. Am J Respir Cell Mol Biol 16 (1997) 171-177
85. Moller D.R. Pulmonary fibrosis of sarcoidosis: new approaches, old ideas. Am J Respir Cell Mol Biol 29 Suppl 3 (2003) S37-S41
86. Rottoli P., Magi B., Perari M.G., et al. Cytokine profile and proteome analysis in BAL of patients with sarcoidosis pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 5 (2005) 1423-1430
87. Wysoczanska B., Bogunia-Kubik K., Suchnicki K., et al. Combined association between IFN-gamma 3,3 homozygosis and DRB1%66D03 in Lofgren's syndrome patients. Immunol Lett 91 (2004) 127-131
88. Baughman R.P., Keeton D., and Lower E.E. Relationship between IL-8 and neutrophils in the BALF of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 11 (1994) S217-S220
89. Shigehara K., Shijubo N., Ohmichi M., et al. IL-12 and IL-18 are increased and stimulate IFN-γ production in sarcoid lungs. J Immunol 166 (2001) 642-649
90. Shigehara K., Shijubo N., Ohmichi M., et al. Increased circulating interleukin-12 (IL-12) p40 in pulmonary sarcoidosis. Clin Exp Immunol 132 (2003) 152-157
91. Sinigaglia F. IL-12 in lung diseases. Sarcoidosis Vasc Diffuse Lung Dis 17 (2000) 122-124
92. Murakozy G., Gaede K.I., Zissel G., et al. Analysis of gene polymorphisms in interleukin-10 and transforming growth factor-ß1 in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 18 (2001) 165-169
93. Kreipe H., Radzun H.J., Heidorn K., et al. Proliferation, macrophage colony-stimulating factor-receptor expression of alveolar macrophage in active sarcoidosis. Lab Invest 62 (1990) 697-703
94. Johansen J.S., Milman N., Hansen M., et al. Increased serum YKL-40 in patients with pulmonary sarcoidosis: a potential marker of disease activity?. Respir Med 99 4 (2005) 396-402
95. Mrazek F., Sekerova V., Drabek J., et al. Expression of the chemokine PARC in BAL of patients with sarcoidosis. Immunol Lett 84 (2002) 17-22
96. Prasse A., Pechkovsky D.V., Toews G.B., et al. A vicious circle of alveolar macrophages and fibroblast perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med 173 (2006) 781-792
97. Matsuyama W., Mitsuyama H., Watanabe M., et al. Involvement of discoidin domain receptor 1 in the deterioration of pulmonary sarcoidosis. Am J Respir Crit Care Med 33 (2005) 565-573
98. Rahman I., Biswas S.K., and Kode A. Oxidant and antioxidant balance in the airways and airway diseases. Eur J Pharmacol 533 (2006) 222-239
99. Das K.K., and Buchner V. Effect of nickel exposure on peripheral tissues: role of oxidative stress in toxicity and possible protection by ascorbic acid. Rev Environ Health 22 (2007) 157-173
100. Baughman R.P., Lower E.E., Pierson G., et al. Spontaneous hydrogen peroxide release from alveolar macrophages of patients with active sarcoidosis: comparison with cigarette smokers. J Lab Clin Med 111 (1998) 399-404
101. Psathakis K., Papatheodorou G., Plataki M., et al. 8-Isoprostane, a marker of oxidative stress, is increased in the expired breath condensate of patients with pulmonary sarcoidosis. Chest 125 (2004) 1005-1011
102. Piotrowski W.J., Antczak A., Marczak J., et al. Eicosanoids in exhaled breath condensate and BAL fluid of patients with sarcoidosis. Chest 132 2 (2007) 589-596
103. Dalle-Donne I., Scaloni A., Giustarini D., et al. Proteins as biomarkers of oxidative/nitrosative stress in diseases: the contribution of redox proteomics. Mass Spectrom Rev 24 (2005) 55-99
104. Rottoli P., Magi B., Cianti R., et al. Carbonylated proteins in BAL of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 5 (2005) 2612-2618
105. Rothkrantz-Kos S., Drent M., Vuil H., et al. Decreased redox state in red blood cells from patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 19 (2002) 114-120
106. Drent M., van den Berg R., Haenen G.R., et al. NF-KappaB activation in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 18 (2001) 50-56
107. Daniele R.P., Dauber J.H., and Rossman M.D. Immunological abnormalities in sarcoidosis. Ann Intern Med 92 (1980) 406-416
108. Sofia M., Mormile M., Faraone S., et al. Endothelin-1 escretion in urine in active pulmonary sarcoidosis and in other interstitial lung diseases. Sarcoidosis 12 (1995) 118-123
109. Reichenberger F., Schauer J., Kellner K., et al. Different expression of endothelin in the BAL in patients with pulmonary diseases. Lung 179 (2001) 163-174
110. Terashita K., Kato S., Sata M., et al. Increased endothelin-1 levels of BAL fluid in patients with pulmonary sarcoidosis. Respirology 11 2 (2006) 145-151
111. Hasday J.D., Backwich P.R., Lynch J.P., et al. Procoagulant and plasminogen activator activities of bronchoalveolar lavage fluid in patients with pulmonary sarcoidosis. Exp Lung Res 14 (1988) 261-278
112. Kobayashi H., Gabazza E.C., Taguch O., et al. Protein C anticoagulant system in patients with interstitial lung disease. Am J Respir Crit Care Med 157 (1998) 1850-1854
113. Shorr A.F., and Hnatiuk O.W. Circulating D dimer in patients with sarcoidosis. Chest 117 (2000) 1012-1016
114. Perez R.L., Kimani A.P., King Jr. T.E., et al. Emory Interstitial Lung Disease Center. Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis. Respiration 74 3 (2007) 297-303
115. Tiitto L., Kaarteenaho-Wiik R., Sormunen R., et al. Expression of the thioredoxin system in interstitial lung disease. J Pathol 201 3 (2003) 363-370
116. Ashitani J., Matsumoto N., and Nakazato M. Elevated alpha-defensin levels in plasma of patients with pulmonary sarcoidosis. Respirology 12 3 (2007) 339-345
117. Drent M., Wirnsberger R.M., de Vries J., et al. Association of fatigue with an acute phase response in sarcoidosis. Eur Respir J 13 (1999) 718-722
118. Salazar A., Pinto X., and Manà J. Serum amyloid A and high-density lipoprotein cholesterol: serum markers of inflammation in sarcoidosis and other systemic disorders. Eur J Clin Invest 31 (2001) 1070-1077
119. Selroos O., and Klockars M. Relation between clinical stage of sarcoidosis and serum values of angiotensin converting enzyme and beta2-microglobulin. Sarcoidosis Vasc Diffuse Lung Dis 4 (1987) 13-17
120. Oksanen V. New cerebrospinal fluid, neurophysiological and neuroradiological examinations in the diagnosis and follow up of neurosarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 4 (1987) 105-110
121. Barnard J., and Newman L.S. Sarcoidosis: immunology, rheumatic diseases, and therapeutics. Curr Opin Rheumatol 13 (2001) 84-91
122. Rottoli P., Gonnelli S., Solitro S., et al. Alterations in calcium metabolism and bone mineral density in relation to the activity of sarcoidosis. Sarcoidosis 10 (1993) 161-162
123. Kauffmann F., and Post Genome Respiratory Epidemiology Group. Post-genome respiratory epidemiology: a multidisciplinary challenge. Eur Respir J 24 3 (2004) 471-480
124. Magi B., Bini L., Perari M.G., et al. BAL fluid protein composition in patients with sarcoidosis and IPF: a 2DE study. Electrophoresis 23 (2002) 3434-3444
125. Wattiez R., and Falmagne P. Proteomics of bronchoalveolar lavage fluid. J Chromatogr B Analyt Technol Biomed Life Sci 815 1-2 (2005) 169-178
126. Sabounchi-Schütt F., Astrom J., Eklund A., et al. Detection and identification of human BAL proteins using narrow-range immobilized pH gradient DryStryp and the paper bridge sample application method. Electrophoresis 22 (2001) 1851-1860
127. Silva E., Bourin S., Sabounchi-Shutt F., et al. A quantitative proteomic analysis of soluble BAL fluid proteins from patients with sarcoidosis and chronic beryllium disease. Sarcoidosis Vasc Diffuse Lung Dis 24 (2007) 24-32
128. Bons J.A., Drent M., Bowman F.G., et al. Potential biomarkers for diagnosis of sarcoidosis using proteomics in serum. Respir Med 101 (2007) 1687-1695
129. Magi B., Bargagli E., Bini L., et al. The proteomic analysis of BAL in lung diseases. Proteomics 6 23 (2006) 6354-6369
130. Lindahl M., Ekstrom T., Sorensen J., et al. Two dimensional protein patterns of BAL fluid from non-smokers, smokers, and subjects exposed to asbestos. Thorax 51 (1996) 1028-1035
131. Sabounchi-Schutt F., Astrom J., Hellman U., et al. Changes in BAL fluid proteins in sarcoidosis: a proteomics approach. Eur Respir J 21 (2003) 414-420
132. Kriegova E., Melle C., Kolek V., et al. Protein profiles of bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 173 10 (2006) 1145-1154
133. Kanazawa N., and Furukawa F. Autoinflammatory syndromes with a dermatological perspective. J Dermatol 34 9 (2007) 601-618
134. Meyer K.C. Bronchoalveolar lavage as a diagnostic tool. Semin Respir Crit Care Med 28 5 (2007) 546-560